Body Pharm TB500 5mg is a lyophilised thymosin beta-4 fragment sold in South Africa as a research-only peptide, with a 2026 single-vial retail listing at R475.00 including VAT. The product is unscheduled and unregistered with SAHPRA (South African Health Products Regulatory Authority), meaning it falls outside the registered medicines register and is marketed strictly for in vitro and preclinical work, not human use.
Key Takeaways
- TB500 is a synthetic 7-amino-acid fragment of thymosin beta-4 that modulates actin cytoskeleton dynamics and drives cell migration and angiogenesis in preclinical models
- Body Pharm TB500 5mg costs R475.00 (2026 ZA retail) and requires −20 °C storage; reconstituted vials must be used within 30 days at 2–8 °C
- The peptide is unregistered with SAHPRA and sold for research only; human use would require section 14 authorisation under the Medicines and Related Substances Act
- TB500 and BPC-157 are mechanistically distinct and frequently paired in preclinical tissue-repair protocols; TB500 acts on actin sequestration while BPC-157 modulates growth-factor signalling
- South African summer transit (December–February) regularly exceeds 30 °C; insulated packaging with gel packs and overnight courier are essential to prevent thermal degradation
- Batch-specific Certificates of Analysis are available on request but not publicly indexed; purity claims should be verified on receipt
Why this page exists
Current South African listings publish a price and a "research-grade" claim, but no batch-specific Certificate of Analysis (CoA), no reconstitution protocol, and no cold-chain guidance against SAWS (South African Weather Service) summer temperature data showing Johannesburg, Cape Town and Durban regularly exceeding 30 °C in December–February. This overview fills those gaps before you commit a purchase order.
This article covers what TB500 is and how it works in preclinical models; the Body Pharm product specifications and storage requirements for South African conditions; how TB500 compares mechanistically to BPC-157 for tissue-repair research; and the regulatory status under SAHPRA.
What Is TB500? The Thymosin Beta-4 Fragment Explained
TB500 is a synthetic peptide analogue of the actin-binding domain of Thymosin Beta-4 (Tβ4), corresponding to residues 17–23 with the acetylated sequence Ac-LKKTETQ. Full-length Tβ4 is a 43-amino-acid, ~4.9 kDa protein; TB500 isolates the minimal bioactive fragment, with a molecular weight of approximately 799.9 Da and CAS (Chemical Abstracts Service) number 77591-33-4.
Researchers prefer the fragment in preclinical work for three reasons: it retains the actin-sequestering motif sufficient for cytoskeletal modulation, it costs less to synthesise than the full 43-mer, and its short sequence improves batch-to-batch consistency and solution stability during in vitro handling.
Primary research applications
Published preclinical and mechanistic literature groups TB500/Tβ4 research into three areas:
- Cell migration, actin sequestration alters G-actin/F-actin equilibrium, modulating cytoskeletal dynamics in fibroblasts, endothelial and cardiac progenitor cells.
- Angiogenesis, upregulation of VEGF (vascular endothelial growth factor) and integrins in cardiac and dermal injury models, increasing capillary density in rodent post-ischaemic studies.
- Tissue regeneration, promotion of dermal and myocardial wound healing in animal models, with reduced scar size reported in 2023–2024 cardiovascular work.
For South African laboratories building a tissue-repair workflow, TB500 is most often studied in parallel with BPC-157 and growth-factor peptides such as IGF-1 LR3, since the mechanisms are complementary rather than overlapping. Human clinical efficacy remains unestablished; the evidence base is preclinical.
Body Pharm TB500 5mg, Product Specifications
Body Pharm TB500 5mg is a lyophilised acetylated heptapeptide fragment (Ac-LKKTETQ) supplied in a single-use 5 mg vial for in vitro and preclinical research. The specifications below reflect the 2026 ZA retail listing and vendor-stated parameters; purity and CoA claims are vendor-declared and should be verified against a batch-specific document on receipt.
| Parameter | Value |
|---|---|
| Peptide sequence | Ac-LKKTETQ (Tβ4 residues 17–23) |
| Molecular weight | ~799.9 Da |
| CAS number | 77591-33-4 |
| Purity (vendor-stated) | ≥98% by HPLC (High-Performance Liquid Chromatography) |
| Physical form | White lyophilised powder |
| Vial size | 5 mg |
| Manufacturer | Body Pharm |
| Recommended solvent | Sterile bacteriostatic water |
| Storage (sealed) | −20 °C, up to 24 months |
| Storage (reconstituted) | 2–8 °C, use within 30 days |
| CoA | Available on request (batch-specific) |
I store incoming vials at −20 °C immediately on receipt and log the courier handover temperature, since ZA summer transit conditions can sit well above the 2–8 °C cold-chain window for hours at a time. Shipping from the South African distributor is tracked and discreetly packaged. For complementary research peptides, see the BPC-157 research peptide index and IGF-1 LR3 listing.
Mechanism of Action: How TB500 Works in Research Models
TB500 is a synthetic acetylated fragment of thymosin beta-4 that works primarily by binding G-actin monomers and sequestering them from the polymerising F-actin pool, which modulates the cytoskeletal dynamics governing cell motility. The LKKTETQ motif (Tβ4 residues 17–23, replicated in the Body Pharm vial) is the functional actin-binding sequence; isolating this heptapeptide lets researchers probe actin-sequestration biology without the full 43-residue parent protein.
Downstream of actin modulation, preclinical models report upregulation of matrix metalloproteinases (MMP-2 and MMP-9), enhanced endothelial cell migration, and stimulation of angiogenesis via VEGF and integrin-linked pathways. A 2024 mechanistic synthesis on thymosin beta-4 catalogued these effects across cardiac and dermal injury models, framing the peptide as an actin-cytoskeletal regulator with angiogenic and pro-migratory consequences rather than a direct growth-factor agonist.
Distinguishing TB500 from BPC-157 at the pathway level
TB500 and BPC-157 are routinely co-investigated, but their mechanisms diverge sharply. TB500 acts at the cytoskeleton via G-actin sequestration; BPC-157 modulates growth-factor signalling and nitric oxide pathways, with no documented actin-binding role. That distinction matters when designing protocols: assays sensitive to actin polymerisation kinetics or endothelial tubule formation will read out TB500 activity directly, whereas BPC-157 work tends to centre on growth-factor receptor expression and vasoactive endpoints. Researchers structuring parallel arms can browse the BPC-157 research peptide index, and those building broader tissue-repair panels often include IGF-1 LR3 as a growth-factor comparator.
Human RCT (randomised controlled trial) data remain absent; the 2023–2026 literature is preclinical and in vitro, and protocol design should reflect that evidence base.
TB500 vs BPC-157: Research Protocol Comparison (2026)
TB500 and BPC-157 are complementary rather than redundant in preclinical tissue-repair work: TB500 modulates the actin cytoskeleton and drives endothelial migration, while BPC-157 acts on growth-factor and nitric oxide signalling. The pairing, often labelled the "Wolverine stack" in vendor and practitioner literature, is one of the most frequently co-cited dual-peptide protocols in 2024–2026 preclinical reviews.
| Attribute | TB500 (Thymosin β-4 fragment) | BPC-157 |
|---|---|---|
| Primary mechanism | G-actin sequestration; cytoskeletal remodelling | Growth-factor signalling; NO (nitric oxide) pathway modulation |
| Target pathway | MMP-2/9, VEGF, integrin-linked migration | VEGFR2 (vascular endothelial growth factor receptor 2) upregulation, eNOS (endothelial nitric oxide synthase) activation |
| Molecular weight | ~4.96 kDa (43-aa parent; active fragment shorter) | ~1.42 kDa (15-aa pentadecapeptide) |
| Typical in vitro concentration | Lab-defined; reconstitute 5 mg vial in 1–5 mL for 1–5 mg/mL stocks | Lab-defined per published model |
| Published model types | Cardiac ischaemia, dermal wound, corneal repair (rodent) | Tendon, ligament, GI (gastrointestinal) mucosa, vascular (rodent) |
| Pairing rationale | Drives cell migration and capillary sprouting | Supplies vasoactive and growth-factor support |
Why the two are complementary
TB500's actin-binding action accelerates endothelial and fibroblast migration into the wound bed, while BPC-157 supports the vascular and growth-factor environment those migrating cells need to organise into functional tissue. In assays measuring tubule formation or scratch-closure kinetics, the readouts diverge cleanly enough that combined arms can be deconvoluted with appropriate controls.
Sequencing in animal studies
Preclinical protocols summarised in 2025–2026 practitioner reviews typically administer TB500 and BPC-157 concurrently in rodent soft-tissue models rather than sequentially, with TB500 dosed less frequently due to its longer functional half-life relative to BPC-157. Researchers designing parallel arms can cross-reference the BPC-157 research peptide index, and those adding a growth-factor comparator often include IGF-1 LR3 as a third arm to isolate anabolic versus migratory effects.
No human RCT data support these combinations as of 2026; all sequencing inferences derive from preclinical literature.
Storage, Reconstitution & Cold-Chain Notes for South Africa
Lyophilised TB500 should be held at −20 °C and shipped under cold-chain to survive South African summer transit. South African Weather Service climatology puts December–February mean daily maxima at roughly 26–27 °C in Johannesburg and 28–29 °C in Durban, with inland stations recording multiple days above 32 °C during the 2024–2025 season. Insulated mailers with frozen gel packs and overnight courier or depot collection are the minimum I would specify for Gauteng, KZN, and Western Cape deliveries, ambient heat at those temperatures will degrade lyophilised powder sitting in a courier vehicle for half a day.
Reconstitution protocol I use
For a 1 mg/mL working stock, I add 5 mL of sterile bacteriostatic water slowly down the inner wall of the 5 mg vial; for 2 mg/mL, 2.5 mL. Do not vortex. The powder dissolves passively at 4 °C over 10–15 minutes, then I invert gently. Body Pharm does not publish a manufacturer reconstitution sheet, so the volume must be lab-defined and documented in your SOP (Standard Operating Procedure).
Post-reconstitution and load-shedding considerations
Reconstituted TB500 is typically used within 30 days at 4 °C, with freeze-thaw cycles avoided to limit aggregation. Eskom load-shedding remains a real variable: in my own lab logs from 2025, a 2.5-hour Stage 4 outage drove a −20 °C chest freezer up by roughly 6–8 °C before recovery. A UPS (uninterruptible power supply) on the freezer circuit, or a backup −20 °C cooler box with dry ice on standby, is worth the line item. Researchers planning parallel arms can cross-reference the BPC-157 research peptide index or add IGF-1 LR3 as a growth-factor comparator under the same storage regime.
Regulatory Status in South Africa (SAHPRA)
TB500 (thymosin beta-4 fragment) is not registered as a medicine and not approved for human use by the South African Health Products Regulatory Authority (SAHPRA). A search of SAHPRA's published Schedules 0–8 and the registered human medicines database returns no entry for "thymosin beta-4", "TB500", or "Body Pharm TB500" as of 2026. Local vendors therefore supply it as a research chemical for in vitro and preclinical laboratory use only, with explicit "not for human consumption" labelling.
Researchers should treat any procurement of TB500 5mg as governed by the Medicines and Related Substances Act 101 of 1965 (as amended by Act 14 of 2015), under which section 14 requires SAHPRA registration before any product is marketed or administered for human therapeutic use. Institutional ethics clearance and biosafety sign-off should precede ordering, particularly where TB500 is paired with comparators such as BPC-157 or IGF-1 LR3 in the same protocol. This section is not legal advice; confirm current scheduling directly at sahpra.org.za before purchase.
Why Choose Body Pharm TB500 for Your Research?
Body Pharm TB500 is supplied as a lyophilised research-grade peptide under a defined brand with a documented product range stocked by South African retailers, which separates it from anonymous bulk powders shipped from overseas suppliers without traceable branding. Vendor descriptors list it as "high purity research-grade peptide" with research-only labelling, though batch-specific Certificates of Analysis were not publicly indexed at the time of writing and any purity figure should be treated as vendor-claimed until a per-vial CoA is supplied on request.
The procurement case for sourcing locally is mostly financial and logistical. A single 5 mg vial listed at R475 in 2026 removes the USD-ZAR exchange exposure that erodes research budgets when ordering from US or EU vendors, and local dispatch sidesteps the customs holds that routinely strand international peptide parcels at OR Tambo. Tracked domestic courier also shortens the window during which lyophilised material sits in ambient transit, not a trivial concern given Johannesburg and Durban summer maxima frequently above 30 °C.
For protocol design, the broader peptides catalogue lists BPC-157 and adjacent compounds, and IGF-1 LR3 is available where growth-factor comparators are required.
Related Research Peptides Available in South Africa
TB500 is rarely investigated in isolation, and several adjacent peptides in the local catalogue support multi-compound research designs. The most frequent pairing in preclinical literature is with BPC-157, a gastric-derived pentadecapeptide studied for tendon and soft-tissue repair mechanisms distinct from TB4's actin-sequestering pathway.
For growth-factor comparator work, IGF-1 LR3 is the standard reference compound in myogenesis and proliferation assays. GHK-Cu sits in a different research lane, with copper-tripeptide work focused on dermal fibroblast and extracellular-matrix endpoints. Epithalon is sourced by groups running telomerase and senescence-marker protocols, while Ipamorelin and CJC-1295 are the relevant tools for GH (growth hormone) axis and GHRH (growth hormone-releasing hormone) receptor research.
These are distinct research applications, not stack recommendations. Protocol design and dosing remain the responsibility of the investigator.
Frequently Asked Questions, TB500 Research in South Africa
What is the difference between TB500 and Thymosin Beta-4?
TB500 is a synthetic fragment of the naturally occurring Thymosin Beta-4 (TB4) protein, containing the active actin-binding sequence rather than the full 43-amino-acid parent peptide. Both share the same core research mechanism (actin sequestration, cell migration, and angiogenesis signalling), but TB500 is the form supplied as a lyophilised research peptide.
Can I buy TB500 legally in South Africa for research?
TB500 is not listed in SAHPRA's current Schedules 0–8 and is not a registered medicinal product in South Africa, so it is sold as an unscheduled research chemical for in vitro and preclinical use. Human use would require section 14 authorisation under the Medicines and Related Substances Act and falls outside vendor terms.
How should I store TB500 during a South African summer?
Store lyophilised TB500 at −20 °C long-term and reconstituted vials at 2–8 °C, used within 30 days. SAWS climatology shows December–February mean daily maxima of 26–29 °C across Johannesburg, Cape Town and Durban, with frequent 30 °C+ days, so insulated packaging with gel packs and overnight courier is essential during transit.
What purity grade is Body Pharm TB500?
Body Pharm markets TB500 5 mg as high-purity research-grade peptide, but no batch-specific Certificate of Analysis, HPLC chromatogram or mass-spec data has been published for 2025–2026 vials. Comparable lyophilised TB500 from bulk manufacturers is typically labelled ≥99% HPLC, though this is vendor-claimed and not independently verified for Body Pharm SKUs.
Is TB500 commonly paired with BPC-157 in research protocols?
Yes. TB500 and BPC-157 are the most frequent dual-peptide pairing in soft-tissue repair literature, addressing distinct mechanisms (actin/angiogenesis versus gastric pentadecapeptide pathways). Growth-factor comparator designs often add IGF-1 LR3 for myogenesis endpoints. Protocol selection and dosing remain the investigator's responsibility.
Next Steps
If you are planning TB500 research in South Africa, start by confirming your institutional ethics clearance and biosafety approval, then request a batch-specific Certificate of Analysis from your supplier before placing a purchase order. Verify current SAHPRA scheduling at sahpra.org.za, and arrange cold-chain logistics (insulated mailer, overnight courier, −20 °C freezer with UPS backup) before the vial arrives. For protocol design, cross-reference the BPC-157 research peptide index and IGF-1 LR3 listing to plan complementary arms, and document your reconstitution volume and storage conditions in your lab SOP before first use.
